OCUGEN INC. - COMMON STOCK

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema

27 2 2023 17:57:17 提供 Nasdaq GlobeNewswire

Ocugen to Present at Retinal Vascular Disease Drug Development Summit

17 2 2023 08:00:00 提供 Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results

15 2 2023 16:30:00 提供 Nasdaq GlobeNewswire

Ocugen Appoints Quan A. Vu as Chief Business Officer

01 2 2023 08:00:01 提供 Nasdaq GlobeNewswire

Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference

31 1 2023 08:00:01 提供 Nasdaq GlobeNewswire

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met

09 1 2023 06:00:00 提供 Nasdaq GlobeNewswire

Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®

16 12 2022 06:30:56 提供 Nasdaq GlobeNewswire

Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis

15 12 2022 17:15:49 提供 Nasdaq GlobeNewswire

Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell

13 12 2022 08:00:02 提供 Nasdaq GlobeNewswire

Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

07 12 2022 08:00:01 提供 Nasdaq GlobeNewswire

Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit

28 11 2022 07:30:00 提供 Nasdaq GlobeNewswire

Ocugen Provides Business Update & Third Quarter 2022 Financial Results

08 11 2022 07:30:34 提供 Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results

27 10 2022 07:30:25 提供 Nasdaq GlobeNewswire

Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022

19 10 2022 07:30:00 提供 Nasdaq GlobeNewswire

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

12 10 2022 17:37:42 提供 Nasdaq GlobeNewswire

Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences

06 10 2022 08:00:28 提供 Nasdaq GlobeNewswire

Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference

29 9 2022 07:30:00 提供 Nasdaq GlobeNewswire

Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan

28 9 2022 06:30:22 提供 Nasdaq GlobeNewswire

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 9 2022 17:07:00 提供 Nasdaq GlobeNewswire

Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology

14 9 2022 06:30:26 提供 Nasdaq GlobeNewswire